UAE R&D Tax Credit Claw-Back, Anti-Abuse & Carry-Forward Rules

What happens to an R&D tax credit after the claim is filed?

Filing the claim starts a compliance obligation that runs for years. UAE R&D tax credit claw-back rules attach conditions to carry-forward, restrict transfers, impose a two-year activity continuation test after restructuring, allow counteraction of artificial fragmentation, and keep a five-year window open during which credits can be unwound. All of it sits behind a credit that already appeared in a filed return.

What makes this genuinely dangerous is that the triggers are not aggressive tax planning. They are ordinary corporate events that a finance director would sign off without a second thought: deregistering an entity that has stopped trading, moving into a free zone, electing a relief the business is plainly entitled to, winding up a dormant subsidiary. Each of those can destroy an accumulated credit balance.

The practical answer is that the R&D credit has to be treated as a standing item in transaction planning, not as a line that closes out with the return. If you have not yet claimed, read the pre-approval and filing process first; if you are building the base, see which costs qualify. This guide covers what happens afterwards.

When can unutilised R&D tax credit be carried forward?

Where the credit exceeds Corporate Tax and Top-up Tax liability for a period, the unutilised balance does not expire — it carries forward as available credit. But the right to use it later is conditional on one of two alternative tests being satisfied at the point of utilisation [VERIFY].

Ownership continuity: the same person or persons who held at least 50% of the entity at the end of the period in which the credit arose still hold that interest at the end of the period in which it is used. Or same business activity: where ownership has changed by more than 50%, the entity carries on the same or a similar business activity across both periods. Fail both and the balance is stranded for that period — it cannot be applied and it cannot be transferred out.

The structure will look familiar to anyone who has dealt with tax losses. It closely mirrors the carry-forward continuity conditions for tax losses in Federal Decree-Law No. 47 of 2022, including the listed-company exemption. That parallel is useful: if your group already tracks ownership continuity for loss carry-forward purposes, extend the same monitoring to the credit register rather than building something separate.

What does “same or similar business activity” actually mean?

There is no bright-line definition, which means the test is fact-specific and decided on the evidence you can produce. A business that has continued to operate the same R&D-driven commercial activity in the same market after an ownership change is in a strong position. One that has pivoted its model, entered a new sector or exited the operations that generated the credit is not.

Because the standard is qualitative, the deciding factor is usually documentation rather than facts. Two businesses in an identical commercial position can reach different outcomes if one recorded the continuity of its activities contemporaneously and the other is reconstructing an argument years later. Board minutes, product roadmaps, customer contracts, licence renewals and the R&D project record itself all serve as evidence that the activity continued.

The point at which to build this record is the point of the ownership change, while the rationale is fresh and the people involved are still in the business. Our accounting and bookkeeping team maintains this alongside the statutory records, and the corporate tax guide for UAE businesses covers the parallel continuity rules for losses.

Can R&D tax credit be transferred to another group entity?

Yes, but the transfer mechanism is far more restrictive than the carry-forward one, and it moves in one direction only. The transferee must be at least 75% commonly owned with the transferor at the date of transfer [VERIFY] — a stricter threshold than the 50% used for ownership continuity, which catches groups that assume one test implies the other.

Two restrictions define what the transferee can do. It cannot carry the credit forward: it must be used in the tax period in which it is received, or it is lost. And it cannot re-transfer: the credit moves once, from the original entity to the first recipient, and stops there. Meanwhile the transferor’s own available balance is permanently reduced by the amount transferred, and the transfer cannot be reversed.

The planning implication is that a transfer should only be made once the receiving entity’s liability for that period is known with reasonable confidence. Transferring in anticipation of a profit that does not materialise converts a carried-forward asset into nothing at all. Model the receiving entity’s position with the UAE corporate tax calculator before executing.

What is the two-year continuation requirement after restructuring?

An entity that has benefited from the R&D tax credit must continue the qualifying R&D activities for at least two years following completion of a business restructuring [VERIFY]. Where the activities are transferred to another entity as part of the reorganisation, that transferee inherits the obligation. The duty follows the activities, not the original legal entity.

Business restructuring here takes its meaning from the restructuring relief provisions of the Corporate Tax Law — mergers, acquisitions, demergers, transfers of business and comparable reorganisations that would otherwise attract relief from the standard realisation rules. That is a broad perimeter, and it catches internal group tidying exercises that nobody thinks of as a transaction.

The reason this deserves attention in due diligence is that the obligation is easy to breach unintentionally. A buyer that acquires an R&D-active business and then rationalises the research programme — consolidating it into an existing team, shelving a project line, relocating the work — may discontinue the qualifying activities inside the window without ever connecting the decision to a tax consequence. The seller has gone; the liability has not.

What happens if R&D stops within two years of a restructuring?

Four consequences apply simultaneously, and they are cumulative rather than alternative [VERIFY]. Repayment: credit already applied against Corporate Tax or Top-up Tax must be repaid in full. Forfeiture: unutilised credit, including carried-forward balances, is permanently lost. No offsetting reliefs: other relief the entity might have applied against the repayment is denied. Penalties as Due Tax: penalties arising are treated as Due Tax, attracting the standard late payment consequences.

Note how little the timing margin was worth. Had the activities continued to March 2029, the position would have been intact. Two months of a research programme that was being wound down anyway carried an AED 800,000 price tag plus penalties — which is precisely why the completion date of any restructuring should be diarised as a tax deadline, not filed as a legal one.

How does the anti-fragmentation rule work?

Where a business, or part of one, has been artificially separated with the primary or principal purpose of accessing the R&D tax credit in a manner inconsistent with the intent of the legislation, the arrangement can be counteracted, the benefit neutralised and the credits clawed back [VERIFY]. There is no fixed time window on this power.

The paradigm case is several related entities each claiming separately for activities that, viewed together, are one research programme — typically structured so that each entity sits just below an expenditure cap that a unified business would have breached. [VERIFY — the existence and level of any expenditure cap is unconfirmed; it is referenced inconsistently across published material on this incentive.]

What the rule does not target is genuine corporate structure. Separate entities pursuing independent research programmes, distinct product lines or separate technology tracks, with their own management, their own IP ownership and their own commercial objectives, are not the mischief. The distinction turns on commercial substance, and substance is proved by contemporaneous evidence of why the structure exists.

If your group runs several R&D-active entities, the review to do now is a substance review: for each entity, can you point to independent management, distinct objectives, its own IP position and a commercial rationale recorded at the time of incorporation? Where related-party arrangements sit between those entities, arm’s length pricing and transfer pricing documentation form part of the same substance case.

What triggers the five-year anti-abuse claw-back?

Five events are listed as triggers, and the window runs for five years from the end of the tax period in which the credit arose [VERIFY]. Critically, the claw-back reaches both utilised and unutilised credits — repayment is required even for amounts already offset against Corporate Tax in earlier years, so this is a live balance-sheet exposure for the full five years, not a restriction on future use.

Does a free zone move or an SBR election really trigger claw-back?

Both are on the trigger list, and the Small Business Relief case is the one that catches ordinary businesses hardest — because SBR is a relief a company is entitled to, elects annually, and would normally take without a second look. Where an R&D credit balance is open, the election can cost many times what it saves.

Small Business Relief is available where revenue does not exceed AED 3,000,000, for tax periods ending on or before 31 December 2029, and must be elected in each period — there is no rolling election. That annual mechanic is what makes the trap avoidable: the decision comes back round every year, so the credit register simply has to be checked before the box is ticked.

The free zone case runs the same way. Becoming a Qualifying Free Zone Person is a legitimate and often advantageous move, but a business holding R&D credits should model the remaining window before migrating. Note too that QFZP status and Small Business Relief are mutually exclusive under the Corporate Tax Law, so a company weighing both options against an open credit balance is choosing between three positions, not two.

Can a restructuring be protected from the anti-abuse claw-back?

Yes. Where the triggering event arises as part of a qualifying business restructuring, the anti-abuse claw-back is disapplied — provided the two-year activity continuation requirement is met and the restructuring has genuine commercial substance [VERIFY]. This is the reason a properly structured and documented reorganisation can survive while an opportunistic regime switch cannot.

The exception is conditional on both limbs, and they pull in opposite directions in practice. Commercial substance is established at the point of the transaction; continuation is proved over the following two years. A restructuring can therefore qualify at completion and fail eighteen months later because the research programme was quietly wound down — at which point the Article 7 consequences arrive instead, which are no softer.

What makes the exception usable is contemporaneous documentation of the commercial rationale: board papers recording the strategic reason for the reorganisation, evidence that the R&D programme was planned to continue, and a monitoring record showing it did. Build this into the transaction file as it happens. Reconstructing commercial substance after a challenge is the weakest position available.

How do you track and protect the credit across the window?

Protection is an ongoing register, not an annual check. The minimum viable system tracks each credit tranche by the tax period it arose in, records the five-year expiry date for that tranche, and is consulted before any transaction completes — not before any return is filed.

1. Log the window start — record the end of the tax period each credit arose in, and diarise the five-year expiry for that tranche specifically.
2. Maintain a tranche-level register — utilised, unutilised, carried forward and transferred amounts by originating period, never as a single consolidated balance.
3. Test carry-forward annually — before including carried-forward credit in a return, confirm ownership continuity or same-business continuation for that period and file the evidence.
4. Screen every transaction pre-completion — deregistration, free zone migration, SBR election, liquidation, redomiciliation and any restructuring go through the register before signature.
5. Document substance as it happens — commercial rationale for group structures and reorganisations recorded when the decision is taken, retained for the full seven-year statutory period.

Seven-year record retention under Federal Decree-Law No. 47 of 2022 outlasts the five-year claw-back window, which is deliberate — the evidence needed to defend a credit has to survive longer than the period in which it can be challenged. Our Corporate Tax filing engagement includes the annual continuity test as standard, and the audit team maintains the supporting file.